Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Conclusion: Final Thoughts on Treating mCRPC

July 10th 2013

Case Study: Managing Symptomatic mCRPC

July 10th 2013

Case Study: Minimally Symptomatic mCRPC

July 10th 2013

Treatment With Sipuleucel-T in Advanced Prostate Cancer

July 10th 2013

Utilizing Early Imaging to Detect Metastatic CRPC

July 10th 2013

Dr. Finkelstein Summarizes the Development of Radium-223

July 10th 2013

Dr. Finkelstein Discusses Radium-223 Reimbursement

July 10th 2013

Dr. Finkelstein Discusses the Safety Profile of Radium-223

July 10th 2013

Dr. Finkelstein Describes the Phase III ALSYMPCA Trial

July 10th 2013

Dr. George on Radium-223 for Patients With mCRPC, Part II

July 10th 2013

Dr. George on Radium-223 for Patients With mCRPC, Part I

July 10th 2013

Case Study: Treating Asymptomatic mCRPC

July 10th 2013

Case Study: Managing Bone Health Following ADT

July 10th 2013

Case Study: Initiating Androgen Deprivation Therapy

July 10th 2013

Case Study: Postoperative Treatment of Prostate Cancer

July 10th 2013

New Investigational Treatments in Prostate Cancer

July 10th 2013

New Treatment Options for Advanced Prostate Cancer

July 10th 2013

Introduction and Overview of CRPC Treatment Challenges

July 10th 2013

Dr. Vogelzang on Two Analyses of the ALSYMPCA Trial

July 10th 2013

Nicholas J. Vogelzang, MD, from the University of Nevada School of Medicine, describes two additional analyses of the phase III ALSYMPCA trial.

Survival Benefit Propels Prostate Cancer Vaccine to Phase III Trial

July 3rd 2013

An investigational prostate cancer vaccine has shown potential to improve survival in patients with metastatic castration-resistant prostate cancer (CRPC).

x